A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
Gaia Griguolo(University of North Carolina at Chapel Hill), Valentina Guarneri(Istituto Oncologico Veneto), Luc Bauchet(Hôpital Gui de Chauliac), PierFranco Conte(University of Padua), Jack Jacob(Alaska Women's Cancer Care), Susan Fineberg(Albert Einstein College of Medicine), Matteo Fassan(University of Padua), William Jacot(Inserm), Valentina Rossi(Istituto Oncologico Veneto), Antonio Rosato(University of Padua), Valérie Rigau(Université de Montpellier), Michele Bottosso(University of Padua), Annavera Ventura(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), Anna Tosi(University of Padua), Federica Miglietta(University of Padua)
Cited by 36
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k